PDCD1 and neoplasm: In AGC, pembrolizumab, a humanized IgG4 monoclonal antibody against programmed cell death-1 (PD-1), can be used as second-line or subsequent treatment for patients with microsatellite instability-high (MSI-H) or tumor mutational burden-high (TMB-H) [11,12].